JELLYFISH
23.2.2021 15:02:15 CET | Business Wire | Press release
Jellyfish , the digital marketing partner to the world's leading brands (i.e., Samsung, Uber, Nestle, Deckers, Spotify, and eBay), announced today the acquisition of 5 companies—each a known leader in the digital space. Jellyfish’s rapid expansion comes against a backdrop of consolidation and challenges in the traditional agency sector as the company’s capabilities lie in helping brands during their digital transformation journey. Jellyfish’s expansion follows previous acquisitions with a significant investment from Fimalac Group in 2019. The company represents a new kind of digital business, where agency services are combined with consultancy, training, and cutting-edge technologies to deliver the best possible outcomes for clients. Launched in 2005, it has also become one of a select few globally managed Google Marketing Platform Partners, growing at an average of 45% per annum consistently over the last eight years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005716/en/
Current eMarketer forecasts indicate that total media ad spend is expected to hit more than 600 billion in 2021 thus, to remain competitive, and to increase media effectiveness, companies must cut through a saturated digital landscape and provide seamless, relevant communications across all channels and touchpoints. The acceleration of digital transformation in response to the global pandemic has created a greater need for brands to partner with companies that can help them navigate and meet the challenges of driving growth and sustainability.
“Our mission is to ensure that our clients have all the resources needed to fully embrace digital transformation and reach results that transcend every expectation. Coming off a year of unprecedented disruption and transformation in digital marketing, Jellyfish continues to grow worldwide, entering new markets of Australia and Mexico and increasing our presence in France, Brazil, and the US—adding new capability and talent around the globe, with a focus on content creation and localization, e-commerce, creative, and data optimization,” says Rob Pierre CEO of Jellyfish. “These acquisitions are key in driving prominence and growth in the marketplace and we believe nothing is impossible or beyond the reach of our clients,” Pierre adds.
“These acquisitions bring powerful enhancements to our portfolio of services by expanding our depth of expertise, geographical reach, and our offerings across several continents and regions,” says Chris Lee, COO, Jellyfish.
Expanded expertise, technologies:
Seelk
Software and consultancy for Amazon Marketplace
Splash
Creative technology and services with global localization
Quill
Global Performance Content for e-commerce
Webedia Brand Services
Gamification, content, data, technology services and enterprise data strategies
Expanded global footprint:
Data Runs Deep - Australia
Consulting, implementation, and training for data solutions
For additional information on each Jellyfish acquisition company, click here .
Other recent acquisitions that expanded our global footprint:
Reamp - Brazil
Programmatic marketing, marketing automation, and digital campaign performance (acquired in H2 2020)
San Pancho - Mexico & Colombia
Full-funnel digital marketing capabilities and analytics expertise (acquired in H2 2020)
About Jellyfish
Jellyfish, part of the Fimalac Group, is a global partner in digital marketing and transformation to some of the world's leading brands including Samsung, Uber, Nestle, Orange, Spotify & eBay. Jellyfish represents a new kind of digital business, where agency services are combined with consultancy, training, and cutting-edge technologies to deliver the best possible outcomes for clients. Employing over 2000 people across 40 offices globally, and with further expansion on the horizon, Jellyfish aims to be the first-choice global partner for any brand’s digital requirements. Launched in 2005, Jellyfish has also grown to become one of a select few globally managed Google Marketing Partners. Growing at an average of 45% per annum consistently over the last eight years, Jellyfish is proud to be at the forefront of the global digital economy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005716/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
